Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sydney C Morgan; Stefan Aigner; Catelyn Anderson; Pedro Belda-Ferre; Peter De Hoff; Clarisse A Marotz; Shashank Sathe; Mark Zeller; Noorsher Ahmed; Xaver Audhya; Nathan A Baer; Tom Barber; Bethany Barrick; Lakshmi Batachari; Maryann Betty; Steven M Blue; Brent Brainard; Tyler Buckley; Jamie Case; Anelizze Castro-Martinez; Marisol Chacon; Willi Cheung; LaVonnye Chong; Nicole G Coufal; Evelyn S Crescini; Scott DeGrand; David P Dimmock; J Joelle Donofrio-Odmann; Emily R Eisner; Mehrbod Estaki; Lizbeth Franco Vargas; Michele Freddock; Robert M Gallant; Andrea Galmozzi; Nina J Gao; Sheldon Gilmer; Edyta M Grzelak; Abbas Hakim; Jonathan Hart; Charlotte Hobbs; Greg Humphrey; Nadja Ilkenhans; Marni Jacobs; Christopher A Kahn; Bhavika K Kapadia; Matthew Kim; Sunil Kurian; Alma L Lastrella; Elijah S Lawrence; Kari Lee; Qishan Liang; Hanna Liliom; Valentina Lo Sardo; Robert Logan; Michal Machnicki; Celestine G Magallanes; Clarence K Mah; Denise Malacki; Ryan J Marina; Christopher Marsh; Natasha K Martin; Nathaniel L Matteson; Daniel J Maunder; Kyle McBride; Bryan McDonald; Daniel McDonald; Michelle McGraw; Audra R Meadows; Michelle Meyer; Amber L Morey; Jasmine R Mueller; Toan T Ngo; Julie Nguyen; Viet Nguyen; Laura J Nicholson; Alhakam Nouri; Victoria Nudell; Eugenio Nunez; Kyle O'Neill; R Tyler Ostrander; Priyadarshini Pantham; Samuel S Park; David Picone; Ashley Plascencia; Isaraphorn Pratumchai; Michael Quigley; Michelle Franc Ragsac; Andrew C Richardson; Refugio Robles-Sikisaka; Christopher A Ruiz; Justin Ryan; Lisa Sacco; Sharada Saraf; Phoebe Seaver; Leigh Sewall; Elizabeth W Smoot; Kathleen M Sweeney; Chandana Tekkatte; Rebecca Tsai; Holly Valentine; Shawn Walsh; August Williams; Min Yi Wu; Bing Xia; Brian Yee; Jason Z Zhang; Kristian G Andersen; Lauge Farnaes; Rob Knight; Gene W Yeo; Louise C Laurent.
Preprint in English | medRxiv | ID: ppmedrxiv-21257885

ABSTRACT

BackgroundSuccessful containment strategies for SARS-CoV-2, the causative virus of the COVID-19 pandemic, have involved widespread population testing that identifies infections early and enables rapid contact tracing. In this study, we developed a rapid and inexpensive RT- qPCR testing pipeline for population-level SARS-CoV-2 detection, and used this pipeline to establish a clinical laboratory dedicated to COVID-19 testing at the University of California San Diego (UCSD) with a processing capacity of 6,000 samples per day and next-day result turnaround times. Methods and findingsUsing this pipeline, we screened 6,786 healthcare workers and first responders, and 21,220 students, faculty, and staff from UCSD. Additionally, we screened 6,031 preschool-grade 12 students and staff from public and private schools across San Diego County that remained fully or partially open for in-person teaching during the pandemic. Between April 17, 2020 and February 5, 2021, participants provided 161,582 nasal swabs that were tested for the presence of SARS-CoV-2. Overall, 752 positive tests were obtained, yielding a test positivity rate of 0.47%. While the presence of symptoms was significantly correlated with higher viral load, most of the COVID-19 positive participants who participated in symptom surveys were asymptomatic at the time of testing. The positivity rate among preschool-grade 12 schools that remained open for in-person teaching was similar to the positivity rate at UCSD and lower than that of San Diego County, with the children in private schools being less likely to test positive than the adults at these schools. ConclusionsMost schools across the United States have been closed for in-person learning for much of the 2020-2021 school year, and their safe reopening is a national priority. However, as there are no vaccines against SARS-CoV-2 currently available to the majority of school-aged children, the traditional strategies of mandatory masking, physical distancing, and repeated viral testing of students and staff remain key components of risk mitigation in these settings. The data presented here suggest that the safety measures and repeated testing actions taken by participating healthcare and educational facilities were effective in preventing outbreaks, and that a similar combination of risk-mitigation strategies and repeated testing may be successfully adopted by other healthcare and educational systems.

2.
Preprint in English | medRxiv | ID: ppmedrxiv-21251159

ABSTRACT

As of January of 2021, the highly transmissible B.1.1.7 variant of SARS-CoV-2, which was first identified in the United Kingdom (U.K.), has gained a strong foothold across the world. Because of the sudden and rapid rise of B.1.1.7, we investigated the prevalence and growth dynamics of this variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission. We found that the RT-qPCR testing anomaly of S gene target failure (SGTF), first observed in the U.K., was a reliable proxy for B.1.1.7 detection. We sequenced 212 B.1.1.7 SARS-CoV-2 genomes collected from testing facilities in the U.S. from December 2020 to January 2021. We found that while the fraction of B.1.1.7 among SGTF samples varied by state, detection of the variant increased at a logistic rate similar to those observed elsewhere, with a doubling rate of a little over a week and an increased transmission rate of 35-45%. By performing time-aware Bayesian phylodynamic analyses, we revealed several independent introductions of B.1.1.7 into the U.S. as early as late November 2020, with onward community transmission enabling the variant to spread to at least 30 states as of January 2021. Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.

SELECTION OF CITATIONS
SEARCH DETAIL
...